Therapeutic Efficacy of Rituximab Combined with Cyclosporin A on B-cell Dysregulation in Chronic Graft-versus-host Disease

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2024 Sep 4

PMID 39231914

Authors

Xiang-Jun Fu

Can Meng

Li Guo

Li-E Lin

Affiliations

Soon will be listed here.

Abstract

Objective: Chronic graft-versus-host disease (cGVHD) is a significant complication following allogenic hematopoietic stem cell transplantation, often necessitating therapeutic interventions such as rituximab (RTX) and cyclosporin A (CsA). This study aims to elucidate the mechanisms by which RTX and CsA jointly address B-cell dysregulation in cGVHD, providing a theoretical foundation and scientific rationale for the treatment and prognostic evaluation of this condition.

Methods: A total of 30 cGVHD mouse models were established by subjecting recipient mice to total body irradiation followed by injection of a mixed suspension of bone marrow cells and splenocytes from donor mice. From Day 2 to Day 29 post-model establishment, the mice received subcutaneous administration of RTX and CsA. Throughout the study, body weight, clinical cGVHD scores, and survival rates were monitored. Blood samples were collected via the orbital venous plexus. Serum levels of B-cell activating factor (BAFF) and pro-inflammatory factors were measured using enzyme-linked immunosorbent assay (ELISA), and the ratio of regulatory B cells (Bregs) in the blood sample was assessed via flow cytometry.

Results: Mice with cGVHD exhibited a 14.5% decrease in body weight, elevated clinical scores, and more severe symptoms compared to the control group. Notably, all mice in both the cGVHD and control groups survived until the conclusion of the study. Induction of cGVHD resulted in B-cell dysregulation, evidenced by elevated serum BAFF levels and a decreased proportion of Bregs. However, treatment with RTX combined with CsA ameliorated B-cell dysregulation and significantly reduced serum levels of pro-inflammatory factors in cGVHD mice, with decreases of 39.78% in TNF-α and 37.89% in IL-6.

Conclusion: The combination of RTX and CsA effectively mitigates B-cell dysregulation in cGVHD, thereby reducing the severity and progression of the disease.

References

Umeda K . Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases. Int J Hematol. 2022; 116(1):41-47. DOI: 10.1007/s12185-022-03361-5. View

Ha J, Park S, Park S, Han S . Metabolic Disease Incidence After Allogeneic Stem Cell Transplantation: A Nationwide Korean Case-Control Study. J Clin Endocrinol Metab. 2021; 107(4):943-952. DOI: 10.1210/clinem/dgab900. View

Burt R, Muraro P, Farge D, Oliveira M, Snowden J, Saccardi R . New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis. Bone Marrow Transplant. 2021; 56(7):1509-1517. DOI: 10.1038/s41409-021-01277-y. View

Yoshimura K, Kimura S, Kawamura M, Kawamura S, Takeshita J, Yoshino N . Chronic liver graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients during tapering or after stopping calcineurin inhibitors. Int J Hematol. 2021; 114(6):674-681. DOI: 10.1007/s12185-021-03202-x. View

Garnett C, Apperley J, Pavlu J . Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol. 2013; 4(6):366-78. PMC: 3854558. DOI: 10.1177/2040620713489842. View

Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D . Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study. Biol Blood Marrow Transplant. 2016; 22(10):1781-1791. DOI: 10.1016/j.bbmt.2016.06.020. View

Arai S, Arora M, Wang T, Spellman S, He W, Couriel D . Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2014; 21(2):266-74. PMC: 4326247. DOI: 10.1016/j.bbmt.2014.10.021. View

McManigle W, Youssef A, Sarantopoulos S . B cells in chronic graft-versus-host disease. Hum Immunol. 2019; 80(6):393-399. PMC: 8049519. DOI: 10.1016/j.humimm.2019.03.003. View

Wan L, Jin Z, Hu B, Lv K, Lei L, Liu Y . IL-Y Aggravates Murine Chronic Graft--Host Disease by Enhancing T and B Cell Responses. Front Immunol. 2020; 11:559740. PMC: 7719702. DOI: 10.3389/fimmu.2020.559740. View

10.

Sarantopoulos S, Stevenson K, Kim H, Cutler C, Bhuiya N, Schowalter M . Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009; 113(16):3865-74. PMC: 2670799. DOI: 10.1182/blood-2008-09-177840. View

11.

Rozmus J, Kariminia A, Abdossamadi S, Storer B, Martin P, Lee S . Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. Biol Blood Marrow Transplant. 2018; 25(3):451-458. PMC: 6445755. DOI: 10.1016/j.bbmt.2018.11.007. View

12.

Thien M, Phan T, Gardam S, Amesbury M, Basten A, Mackay F . Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004; 20(6):785-98. DOI: 10.1016/j.immuni.2004.05.010. View

13.

Moore D, Loxton A . Regulatory B lymphocytes: development and modulation of the host immune response during disease. Immunotherapy. 2019; 11(8):691-704. DOI: 10.2217/imt-2018-0185. View

14.

Pacaud M, Colas L, Brouard S . Microbiota and immunoregulation: A focus on regulatory B lymphocytes and transplantation. Am J Transplant. 2021; 21(7):2341-2347. DOI: 10.1111/ajt.16522. View

15.

Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N . Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. Blood. 2014; 124(13):2034-45. PMC: 4186534. DOI: 10.1182/blood-2014-04-571125. View

16.

Rosser E, Mauri C . Regulatory B cells: origin, phenotype, and function. Immunity. 2015; 42(4):607-12. DOI: 10.1016/j.immuni.2015.04.005. View

17.

Li J, Gao J, Zhou H, Zhou J, Deng Z, Lu Y . Inhibition of Glycogen Synthase Kinase 3β Increases the Proportion and Suppressive Function of CD19CD24CD27 Breg Cells. Front Immunol. 2020; 11:603288. PMC: 7746849. DOI: 10.3389/fimmu.2020.603288. View

18.

Qin Z, Ruan J, Lee M, Sun K, Chen P, Chen Y . Mangiferin Promotes Bregs Level, Activates Nrf2 Antioxidant Signaling, and Inhibits Proinflammatory Cytokine Expression in Murine Splenic Mononuclear Cells In Vitro. Curr Med Sci. 2021; 41(3):454-464. DOI: 10.1007/s11596-021-2371-9. View

19.

Gonzalez R, Pidala J . Evolving Therapeutic Options for Chronic Graft-versus-Host Disease. Pharmacotherapy. 2020; 40(8):756-772. DOI: 10.1002/phar.2427. View

20.

Baker M, McKiernan P . Management of chronic graft-versus-host disease. Clin J Oncol Nurs. 2011; 15(4):429-32. DOI: 10.1188/11.CJON.429-432. View